Compare PKX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKX | GH |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 13.3B |
| IPO Year | 1998 | 2018 |
| Metric | PKX | GH |
|---|---|---|
| Price | $59.68 | $90.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $117.80 |
| AVG Volume (30 Days) | 158.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $5.89 | $33.40 |
| Revenue Next Year | $3.90 | $28.55 |
| P/E Ratio | $42.95 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $40.80 | $36.36 |
| 52 Week High | $71.35 | $120.74 |
| Indicator | PKX | GH |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 34.26 |
| Support Level | $58.83 | $89.32 |
| Resistance Level | $61.24 | $114.53 |
| Average True Range (ATR) | 1.90 | 5.32 |
| MACD | -1.34 | -0.60 |
| Stochastic Oscillator | 15.49 | 10.09 |
POSCO Holdings Inc is a holding company and operates through its subsidiaries. The company operates across four distinct segments. The first segment is the Steel Segment, which includes the production and sale of steel products. The second segment is the Infrastructure Business, which is further divided into three operations. The Trading Segment comprises trading and natural resource development activities. The Construction Segment involves the planning, designing, and construction of industrial plants, civil engineering projects, and buildings. The Logistics and Others Segment. The third segment is the Secondary Battery Materials Segment, and the fourth segment is the Others Segment.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.